Diversity and inclusion: The business case for building more equitable organizations
Journal of Management and Science · 31.12.2021 · 11 (4) · 88-90
DOI: 10.26524/jms.11.51 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Management and Science, online erschienen am 31.12.2021. Verfasst von Lakshmi Kalyani Chinthala. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Diversity and inclusion (D&I) have become central pillars in modern organizational strategy. This paper explores the business case for diversity and inclusion, focusing on how diverse teams and inclusive cultures drive innovation, enhance employee engagement, and improve financial performance. The paper discusses the key factors that contribute to successful D&I initiatives, including leadership commitment, inclusive recruitment practices, and the creation of a psychologically safe environment. It also examines the challenges organizations face in implementing effective D&I strategies, such as unconscious bias, resistance to change, and measuring progress. Finally, the paper highlights the long-term benefits of fostering diversity and inclusion in the workplace, emphasizing how organizations that prioritize these values are better positioned to adapt to changing demographics, attract top talent, and create more sustainable business models.
Zitieren
APA
Chinthala, L. K. (2021). Diversity and inclusion: The business case for building more equitable organizations. Journal of Management and Science, 11(4), 88-90. https://doi.org/10.26524/jms.11.51
Vancouver
Chinthala LK. Diversity and inclusion: The business case for building more equitable organizations. Journal of Management and Science. 2021;11(4):88-90. doi:10.26524/jms.11.51
BibTeX
@article{Chinthala2021,
author = {Chinthala, Lakshmi Kalyani},
title = {Diversity and inclusion: The business case for building more equitable organizations},
journal = {Journal of Management and Science},
year = {2021},
volume = {11},
number = {4},
pages = {88--90},
doi = {10.26524/jms.11.51}
}
EUVIMED